Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 4/20 | 0.45 |
| ▸ | BMX | P51813 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2163811 | 0.83 | ALDH1A1 (0.52) | FLT3BMXALDH1A1HSD17B10KDM4E | |
| SCHEMBL2162771 | 0.83 | RAD51 (0.41) | FLT3BMXALDH1A1HSD17B10KDM4E | |
| SCHEMBL12403623 | 0.81 | ADORA2A (0.41) | HSD17B10CYP3A4ADORA2AADORA1RAD51 | |
| SCHEMBL12402976 | 0.81 | KDM4E (0.44) | FLT3ALDH1A1HSD17B10KDM4ENPC1 | |
| SCHEMBL2162664 | 0.81 | RAD51 (0.40) | ADORA2AADORA1RAD51 | |
| Bromide SCHEMBL2163717 | 0.81 | ADORA2A (0.41) | HSD17B10CYP3A4ADORA2AADORA1RAD51 | |
| SCHEMBL2162709 | 0.80 | ADORA2A (0.56) | FLT3ALDH1A1HSD17B10TSHRKDM4E | |
| SCHEMBL2163292 | 0.79 | RAD51 (0.40) | ADORA2AADORA1RAD51 | |
| SCHEMBL2163735 | 0.79 | ADORA2A (0.59) | FLT3ALDH1A1HSD17B10CYP3A4TSHR | |
| SCHEMBL31307040 | 0.79 | ADORA2A (0.46) | FLT3ALDH1A1CYP3A4TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2550255-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2550255-A1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | Siemens Medical Solutions USA, Inc. (US) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011119565-A1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | MAPT, APP, PSEN1 | FLT3 3289/4885BMX 1662/4885ALDH1A1 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.